MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Integra LifeSciences Holdings Corp

Slēgts

SektorsVeselības aprūpe

12.41 -1.74

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.31

Max

12.62

Galvenie mērījumi

By Trading Economics

Ienākumi

479M

-5.4M

Pārdošana

-14M

402M

Peļņas marža

-1.344

Darbinieki

4,396

EBITDA

526M

54M

Rekomendācijas

By TipRanks

Rekomendācijas

Pārdot

Prognoze 12 mēnešiem

-1.6% downside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 24. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-231M

1B

Iepriekšējā atvēršanas cena

14.15

Iepriekšējā slēgšanas cena

12.41

Ziņu noskaņojums

By Acuity

40%

60%

129 / 361 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Integra LifeSciences Holdings Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 16. janv. 23:29 UTC

Karstas akcijas

Stocks to Watch: Atossa Therapeutics, Union Pacific

2026. g. 16. janv. 22:48 UTC

Iegādes, apvienošanās, pārņemšana

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

2026. g. 16. janv. 22:43 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

2026. g. 16. janv. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

2026. g. 16. janv. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 16. janv. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Auto & Transport Roundup: Market Talk

2026. g. 16. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 16. janv. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 16. janv. 21:48 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

2026. g. 16. janv. 21:41 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

2026. g. 16. janv. 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

2026. g. 16. janv. 21:30 UTC

Iegādes, apvienošanās, pārņemšana

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

2026. g. 16. janv. 20:44 UTC

Peļņas

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

2026. g. 16. janv. 20:42 UTC

Tirgus saruna

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

2026. g. 16. janv. 20:28 UTC

Tirgus saruna

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

2026. g. 16. janv. 19:12 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

2026. g. 16. janv. 18:53 UTC

Tirgus saruna

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

2026. g. 16. janv. 18:41 UTC

Tirgus saruna

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

2026. g. 16. janv. 18:31 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

2026. g. 16. janv. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 16. janv. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 16. janv. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 16. janv. 17:03 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 16. janv. 17:03 UTC

Tirgus saruna

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

2026. g. 16. janv. 16:32 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

2026. g. 16. janv. 16:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Integra LifeSciences Holdings Corp Prognoze

Cenas mērķis

By TipRanks

-1.6% uz leju

Prognoze 12 mēnešiem

Vidējais 12.33 USD  -1.6%

Augstākais 14 USD

Zemākais 10 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Integra LifeSciences Holdings Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pārdot

6 ratings

0

Pirkt

2

Turēt

4

Pārdot

Tehniskais rādītājs

By Trading Central

12.75 / 16.41Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

129 / 361 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Integra LifeSciences Holdings Corp

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
help-icon Live chat